Protected PCI


Protected PCI Enables Safe and Effective Treatment of High-Risk and Complex Patients

Benefits of Protected PCI include:

  • Improved outcomes through complete revascularization and reduction of repeat and staged procedures5
  • Improvement in ejection fraction and heart failure symptoms1
  • Significant reduction in the overall incidence of post-procedural acute kidney injury (AKI)2
  • Fewer hypotensive events during the procedure1
  • Reduction in peri-procedural MI and post-procedural MACCE3
  • Treatment options for patients ineligible for surgery4
  • Reduction in length of stay6


Read more about the procedural steps for the single-access technique that enables one access site for both the Impella CP® and an additional catheter.

Download PDF

Best Practices for Safe Femoral Access and Closure

Rajan Patel, MD, presents a series of case studies highlighting management and troubleshooting techniques for femoral artery access and closure.

Resources from the Education Library


Complete Revascularization Associated with Significant Improvement in LVEF and Long-Term Survival

This study was a retrospective study at 2 centers in Rome and Verona, Italy using a prospectively maintained registry database.


Rapid and Safe Adoption of the New Single Access Technique

Duane Pinto, MD, MPH, discusses the new single access technique, designed to avoid an additional arterial access, and reduce associated complications as well as make the procedure more rapid.


Complex Percutaneous Axillary Protected PCI Case

Watch Thom Dahle, MD, perform a high-risk PCI procedure recorded live from St. Cloud, MN, with panel commentary.

Image of a physician using a tablet with a blue hash pattern overlay

Abiomed Academy provides self-guided online product training for health care professionals of all experience levels and roles.




Patient Management

Learn more about the ICU management of patients, decision-making for weaning and escalation, and pump management


  1. O’Neill, W.W., et al. (2012). Circulation, 126(14), 1717-1727.
  2. Flaherty, M.P., et al. (2017). Circ Res, 120(4), 692-700.
  3. Dangas, G.D., et al. (2014). Am J Cardiol, 113(2), 222-228.
  4. Waldo, S.W., et al. (2014). Circulation, 130(25), 2295-2301.
  5. Burzotta, F., et al. (2019). J Interv Cardiol, 2019(5), 1-10.
  6. Maini, B., et al. (2014). Expert Rev Pharmacoecon Outcomes Res, 14(3), 403-416.